Physician profile
David L Bajor
NPI 1811102205
$4,305.60
in general payments reported to CMS, 2019-2025
23 companies · $2,562 in 2025
The $2,562 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,403 · 2023: $154 · 2024: $186 · 2025: $2,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,920 · Food and Beverage: $982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,920.00 |
| Food and Beverage | $982.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $2,098.73 | 2025 | Korlym |
| Seagen INC. | $1,375.00 | 2022 | |
| Exelixis INC. | $168.05 | 2025 | Cabometyx |
| Eisai INC. | $157.87 | 2023-2025 | |
| Pfizer INC. | $147.31 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $82.64 | 2022-2024 | |
| Abbvie INC. | $56.85 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $40.12 | 2023 | Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $35.04 | 2023 | |
| Merck Sharp & Dohme LLC | $32.81 | 2024 | Keytruda, Welireg, Lynparza |
| Genentech USA, INC. | $27.26 | 2024 | Tecentriq |
| Amgen INC. | $24.34 | 2023 | Lumakras |
| Janssen Biotech, INC. | $16.09 | 2025 | Talvey, Darzalex |
| Incyte Corporation | $15.82 | 2025 | Monjuvi, Pemazyre |
| Becton, Dickinson and Company | $13.88 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $13.79 | 2024 | Ogsiveo |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bajor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.